7.67亿孤注一掷!君实生物豪赌双抗生死局

新浪财经
Jun 11, 2025

近日 君实生物 一则募资用途调整公告在 资本市场 掀起波澜。这家曾经创造国产PD-1首个美国上市纪录的 创新药 企,正以近乎壮士断腕的姿态调整战略方向——将7.67亿元募集资金集中投向PD-1/VEGF双抗JS207,同时削减14个在研项目投入。对于二级市场投资者而言,这一决策背后折射出的不仅是企业生存策略的转变,更代表着中国创新药产业从野蛮生长向理性发展过渡期的典型投资样本。公告次日股价...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10